Arcutis Ebit Per Revenue from 2010 to 2024
| ARQT Stock | USD 10.77 0.63 6.21% |
Ebit Per Revenue | First Reported 2010-12-31 | Previous Quarter (4.04) | Current Value (4.25) | Quarterly Volatility 27.33401077 |
Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 31.2 M, Selling General Administrative of 182.2 M or Total Revenue of 62.6 M, as well as many indicators such as Price To Sales Ratio of 3.57, Dividend Yield of 0.0 or PTB Ratio of 2.65. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
Arcutis | Ebit Per Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.